Insider Selling: Cardlytics, Inc. (NASDAQ:CDLX) Insider Sells 3,377 Shares of Stock

Cardlytics, Inc. (NASDAQ:CDLX) insider Nicholas Hollmeyer Lynton sold 3,377 shares of Cardlytics stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $3.19, for a total value of $10,772.63. Following the sale, the insider now owns 94,706 shares of the company’s stock, valued at approximately $302,112.14. This trade represents a 3.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Nicholas Hollmeyer Lynton also recently made the following trade(s):

• On Friday, January 3rd, Nicholas Hollmeyer Lynton sold 6,464 shares of Cardlytics stock. The shares were sold at an average price of $3.67, for a total transaction of $23,722.88.

Cardlytics Stock Performance

Cardlytics stock opened at $3.06 on Friday. The firm has a fifty day simple moving average of $3.62 and a two-hundred day simple moving average of $4.19. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 2.40. Cardlytics, Inc. has a twelve month low of $2.76 and a twelve month high of $20.52. The company has a market capitalization of $155.51 million, a PE ratio of -0.50 and a beta of 1.53.

Cardlytics (NASDAQ:CDLX) last released its earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.18. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The company had revenue of $67.06 million during the quarter, compared to analyst estimates of $57.77 million. During the same quarter in the previous year, the company posted ($0.26) EPS. Cardlytics’s revenue for the quarter was down 15.1% on a year-over-year basis. Research analysts expect that Cardlytics, Inc. will post -1.52 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Check Capital Management Inc. CA boosted its position in Cardlytics by 10.4% during the 3rd quarter. Check Capital Management Inc. CA now owns 50,650 shares of the company’s stock valued at $162,000 after buying an additional 4,775 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Cardlytics by 32.1% during the third quarter. BNP Paribas Financial Markets now owns 19,745 shares of the company’s stock valued at $63,000 after acquiring an additional 4,796 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of Cardlytics by 38.2% during the fourth quarter. SG Americas Securities LLC now owns 19,490 shares of the company’s stock worth $72,000 after purchasing an additional 5,392 shares during the period. Global Retirement Partners LLC boosted its holdings in shares of Cardlytics by 54.7% during the fourth quarter. Global Retirement Partners LLC now owns 19,800 shares of the company’s stock worth $73,000 after purchasing an additional 7,000 shares during the period. Finally, Creative Planning grew its stake in shares of Cardlytics by 35.4% in the third quarter. Creative Planning now owns 29,537 shares of the company’s stock worth $95,000 after purchasing an additional 7,721 shares during the last quarter. Institutional investors own 68.10% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on CDLX shares. Needham & Company LLC reissued a “hold” rating on shares of Cardlytics in a report on Friday, January 17th. Craig Hallum raised Cardlytics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. Finally, Evercore ISI initiated coverage on Cardlytics in a research note on Friday, October 11th. They set an “in-line” rating and a $4.00 price target for the company. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Cardlytics has an average rating of “Hold” and an average target price of $6.92.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.